EYE-FIT is a randomized clinical trial with a two-arm parallel design aimed at assessing the impact of performing a structured and supervised physical training program on the different variables associated with glaucoma progression in pharmacologically treated primary open angle glaucoma patients. This intervention will include a supervised 24-weeks concurrent (endurance + resistance) training program comparing its influence to the standard care.
There are claims that more physically active individuals are less likely to glaucoma onset and progression. However, to date, there is not a single randomized controlled clinical trial assessing the impact of performing a structured and supervised physical training program on glaucoma progression. A randomized controlled clinical trial with a two-arm parallel design will be used to determine the chronic effects of a 24-weeks concurrent (endurance + resistance) training program in comparison to a control group (no training prescribed) on the ocular function and physical fitness of primary open angle glaucoma patients. Participants will be randomly divided in one of the two groups (experimental or control \[wait-list\]), while ocular function and physical fitness will be assessed before and after the intervention by researchers blinded to the group allocation of each participant. In addition, primary open angle glaucoma patients will be subdivided according to their medical treatment in two groups (prostaglandin analogues and combination of prostaglandin analogue and beta-blockers). Therefore, four groups will be considered in this clinical trial. The results of the EYE-FIT clinical trial will provide novel information on the influence of exercise on different markers of glaucoma, and may help to reduce the clinical, economic and social burden of this disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
136
University of Granada
Granada, Spain
Change from baseline glaucomatous damage in the retina at 6 months
Optical coherence tomography for the assessment of glaucomatous damage in the macula and optic nerve head
Time frame: Baseline (week 0) and after-intervention (week 25)
Change from baseline visual fields at 6 months
Evaluation of the visual fields with the Humphrey Field Analyzer using the Swedish Interactive Thresholding Algorithm (24-2) SITA-Standard protocol .
Time frame: Baseline (week 0) and after-intervention (week 25)
Changes from baseline anterior eye morphology and corneal biomechanics at 6 months
Assessment of the anterior chamber morphology using the Pentacam Scheimpflug camera and the biomechanics of the cornea using the Corvis ST.
Time frame: Baseline (week 0) and after-intervention (week 25)
Change from baseline electrophysiological activity in the retina at 6 months
Examination of the functional state of the retina with the photopic negative response and pattern ERG
Time frame: Baseline (week 0) and after-intervention (week 25)
Change from baseline intraocular pressure at 6 months
Assessment of intraocular pressure levels
Time frame: Baseline (week 0) and after-intervention (week 25)
Change from baseline ocular perfusion pressure at 6 months
Indirect calculation of ocular perfusion pressure by the measure of intraocular pressure and blood pressure
Time frame: Baseline (week 0) and after-intervention (week 25)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Self-reported vision-targeted health status
The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Minimum value: 0 // Maximum value: 100. Higher scores mean a better outcome.
Time frame: Baseline (week 0) and after-intervention (week 25)
Glaucoma-specific questionnaire
The Glaucoma Symptom Scale (GSS). Minimum value: 0 // Maximum value: 100. Higher scores mean a better outcome.
Time frame: Baseline (week 0) and after-intervention (week 25)
Glaucoma-related quality of life
The 15-item Glaucoma Quality of Life (GQL-15). Minimum value: 0 // Maximum value: 100. Higher scores mean a worse outcome.
Time frame: Baseline (week 0) and after-intervention (week 25)
Health-related quality of life
The 36-Item Short Form Health Survey questionnaire (SF-36). Minimum value: 0 // Maximum value: 100. Higher scores mean a better outcome.
Time frame: Baseline (week 0) and after-intervention (week 25)
Self-rated health in mobility, self-care, usual activities, pain/discomfort and anxiety/depression
The EuroQol Group inventory of 5 dimensions and 3 levels (EQ-5D-3L). Minimum value: 0 // Maximum value: 1. Higher scores mean a better outcome.
Time frame: Baseline (week 0) and after-intervention (week 25)
Assessment of emotional (hedonic), social and psychological well-being.
The Mental Health Continuum-Short Form (MHC-SF). Minimum value: 0 // Maximum value: 70. Higher scores mean a better outcome.
Time frame: Baseline (week 0) and after-intervention (week 25)
Distress evaluation along the 3 axes of depression, anxiety and stress
The Depression, Anxiety and Stress Scale short form (DASS-21). Minimum value: 0 // Maximum value: 21. Higher scores mean a worse outcome.
Time frame: Baseline (week 0) and after-intervention (week 25)
Strength performance
Evaluation of the velocity recorded against submaximal loads with a linear position transducer in the squat and bench press exercises.
Time frame: Baseline (week 0) and after-intervention (week 25)
Endurance performance
An incremental loading test will be performed on a leg crank ergometer
Time frame: Baseline (week 0) and after-intervention (week 25)
Weight
Weight measured with a scale (kg).
Time frame: Baseline (week 0) and after-intervention (week 25)
Fat mass
Body composition assessment will be obtained through a segmental multi-frequency body composition analyzer. Fat mass in kg.
Time frame: Baseline (week 0) and after-intervention (week 25)
Lean mass
Body composition assessment will be obtained through a segmental multi-frequency body composition analyzer. Lean mass in kg.
Time frame: Baseline (week 0) and after-intervention (week 25)
Visceral adipose tissue
Body composition assessment will be obtained through a segmental multi-frequency body composition analyzer. Visceral adipose tissue in kg.
Time frame: Baseline (week 0) and after-intervention (week 25)